keyword
https://read.qxmd.com/read/38514195/dural-metastasis-in-breast-cancer-mri-based-morphological-subtypes-and-their-clinical-implications
#21
JOURNAL ARTICLE
Sung Jun Ahn, Bio Joo, Mina Park, Hun Ho Park, Sang Hyun Suh, Sung Gwe Ahn, Jihwan Yoo
PURPOSE: To investigate the clinical factors associated with breast cancer (BRCA) dural metastases (DMs), their impact on prognosis compared to brain parenchymal metastases (BPMs) alone, and differences between DM subtypes, aiming to inform clinical decisions. MATERIALS AND METHODS: We retrospectively analyzed 119 patients with BRCA with brain metastasis, including 91 patients with BPM alone and 28 patients with DM. Univariate and multivariate analyses were performed to compare the clinical characteristics between the two groups and within subtypes of DM...
March 19, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38484298/deciphering-breast-cancer-metastasis-cascade-a-systems-biology-approach-integrating-transcriptome-and-interactome-insights-for-target-discovery
#22
JOURNAL ARTICLE
Bikashita Kalita, Mohane Selvaraj Coumar
Breast cancer is the lead cause of cancer-related deaths among women globally. Breast cancer metastasis is a complex and still inadequately understood process and a key dimension of mortality attendant to breast cancer. This study reports dysregulated genes across metastatic stages and tissues, shedding light on their molecular interplay in disease pathogenesis and new possibilities for drug discovery. Comprehensive analyses of gene expression data from primary breast tumor, circulating tumor cells, and distant metastatic sites in the brain, lung, liver, and bone were conducted...
March 14, 2024: Omics: a Journal of Integrative Biology
https://read.qxmd.com/read/38483275/-o-glycome-profiling-of-breast-cancer-cell-lines-to-understand-breast-cancer-brain-metastasis
#23
JOURNAL ARTICLE
Sherifdeen Onigbinde, Wenjing Peng, Akhila Reddy, Byeong Gwan Cho, Mona Goli, Joy Solomon, Moyinoluwa Adeniyi, Judith Nwaiwu, Mojibola Fowowe, Oluwatosin Daramola, Waziha Purba, Yehia Mechref
Breast cancer is the second leading cause of cancer-related death among women and a major source of brain metastases. Despite the increasing incidence of brain metastasis from breast cancer, the underlying mechanisms remain poorly understood. Altered glycosylation is known to play a role in various diseases including cancer metastasis. However, profiling studies of O -glycans and their isomers in breast cancer brain metastasis (BCBM) are scarce. This study analyzed the expression of O -glycans and their isomers in human breast cancer cell lines (MDA-MB-231, MDA-MB-361, HTB131, and HTB22), a brain cancer cell line (CRL-1620), and a brain metastatic breast cancer cell line (MDA-MB-231BR) using nanoLC-MS/MS, identifying 27 O -glycan compositions...
March 14, 2024: Journal of Proteome Research
https://read.qxmd.com/read/38480976/adeno-associated-virus-mediated-trastuzumab-delivery-to-the-central-nervous-system-for-human-epidermal-growth-factor-receptor-2-brain-metastasis
#24
JOURNAL ARTICLE
Marcela S Werner, Shweta Aras, Ashleigh R Morgan, Jillian Roamer, Nesteene J Param, Kanyin Olagbegi, R Jason Lamontagne, Jenny A Greig, James M Wilson
Trastuzumab improves overall survival for HER2+ breast cancer, but its short half-life in the cerebrospinal fluid (~2-4 days) and delivery limitations restrict the ability to target HER2+ central nervous system (CNS) disease. We developed an adeno-associated virus (AAV) vector expressing a codon-optimized, ubiquitin C (UbC)-promoter-driven trastuzumab sequence (AAV9.UbC.trastuzumab) for intrathecal administration. Transgene expression was evaluated in adult Rag1 knockout mice and rhesus nonhuman primates (NHPs) after a single intracerebroventricular (ICV) or intra-cisterna magna (ICM) AAV9...
March 13, 2024: Cancer Gene Therapy
https://read.qxmd.com/read/38473273/breast-tumor-metastasis-and-its-microenvironment-it-takes-both-seed-and-soil-to-grow-a-tumor-and-target-it-for-treatment
#25
REVIEW
Shirin Bonni, David N Brindley, M Dean Chamberlain, Nima Daneshvar-Baghbadorani, Andrew Freywald, Denise G Hemmings, Sabine Hombach-Klonisch, Thomas Klonisch, Afshin Raouf, Carrie Simone Shemanko, Diana Topolnitska, Kaitlyn Visser, Franco J Vizeacoumar, Edwin Wang, Spencer B Gibson
Metastasis remains a major challenge in treating breast cancer. Breast tumors metastasize to organ-specific locations such as the brain, lungs, and bone, but why some organs are favored over others remains unclear. Breast tumors also show heterogeneity, plasticity, and distinct microenvironments. This contributes to treatment failure and relapse. The interaction of breast cancer cells with their metastatic microenvironment has led to the concept that primary breast cancer cells act as seeds, whereas the metastatic tissue microenvironment (TME) is the soil...
February 23, 2024: Cancers
https://read.qxmd.com/read/38472273/retraction-note-human-induced-pluripotent-stem-cell-derived-platelets-loaded-with-lapatinib-effectively-target-her2-breast-cancer-metastasis-to-the-brain
#26
Arunoday Bhan, Khairul Ansari, Mike Y Chen, Rahul Jandial
No abstract text is available yet for this article.
March 12, 2024: Scientific Reports
https://read.qxmd.com/read/38460250/comprehensive-genomic-profiling-to-identify-actionable-alterations-for-breast-cancer-brain-metastases-in-the-chinese-population
#27
JOURNAL ARTICLE
Q Lu, N Wang, K Jiang, H Zhou, P Zhang, J Zhang, S Wang, P Sun, F Xu
BACKGROUND: Breast cancer brain metastasis (BCBM) is a crucial issue in the treatment of breast cancer and is associated with poor prognosis. Therefore, novel therapeutic targets are urgently needed in clinical practice. In this study, we aimed to identify potential actionable targets in brain metastases (BMs) utilising the FoundationOne® CDx (F1CDx). PATIENTS AND METHODS: Formalin-fixed paraffin-embedded archived specimens including 16 primary breast tumours (PTs), 49 BCBMs and 7 extracranial metastases (ECMs) from 54 patients who underwent surgery for BCBM were tested using F1CDx...
March 8, 2024: ESMO Open
https://read.qxmd.com/read/38455134/bridging-the-gap-predicting-brain-metastasis-in-breast-cancer
#28
JOURNAL ARTICLE
Daniela Gonsalves, Raquel Ciérvide, Felipe Couñago
Chen et al explored clinicopathological features and prognostic factors, revealing advanced tumor stage, lung metastases, HER-2 overexpression, and triple-negative status as key contributors. Recent research connects astrocytes' role in brain metastasis with signaling pathways and the impact of Trastuzumab on HER-2 tumor survival. Factors such as positive HER2 status, lack of estrogen receptor expression, and liver metastasis are identified as additional risk factors. The routine use of magnetic resonance imaging, insights into gene mutations associated with metastasis, and the role of radiotherapy, including prophylaxis possibilities, is controversial in clinical practice...
February 24, 2024: World Journal of Clinical Oncology
https://read.qxmd.com/read/38430420/prognostic-impact-of-clinical-and-radiological-factors-on-leptomeningeal-metastasis-from-solid-cancers
#29
JOURNAL ARTICLE
Kanji Nakagawa, Koji Takano, Kazumi Nishino, Shuichi Ohe, Takahiro Nakayama, Hideyuki Arita
PURPOSE: The number of leptomeningeal metastasis (LM) patients has increased in recent years, as the cancer survival rates increased. An optimal prediction of prognosis is essential for selecting an appropriate treatment. The European Association of Neuro-Oncology-European Society for Medical Oncology (EANO-ESMO) guidelines for LM proposed a classification based on the cerebrospinal fluid cytological findings and contrast-enhanced magnetic resonance imaging (MRI) pattern. However, few studies have validated the utility of this classification...
March 2, 2024: Journal of Neuro-oncology
https://read.qxmd.com/read/38426438/a-biodegradable-nanosuspension-locally-used-for-inhibiting-postoperative-recurrence-and-brain-metastasis-of-breast-cancer
#30
JOURNAL ARTICLE
Min Qian, Guangwei Jiang, Wei Guo, Rongqin Huang
Addressing the urgent need to prevent breast cancer postoperative recurrence and brain metastasis, Fe-metal organic framework (MOF)-coated hollow mesoporous organosilica nanoparticles (HMON) with tumor microenvironment dual-responsive degradability were prepared to encapsulate doxorubicin (DOX), formulating a tissue-adhesive nanosuspension for perioperative topical medication. This nanosuspension can not only retain the sustainably released drug in the postoperative residual tumor sites but also enhance the intracellular oxidative stress of tumors for remarkable tumor ferroptosis...
March 1, 2024: Nano Letters
https://read.qxmd.com/read/38426391/investigation-of-the-risk-factors-in-the-development-of-radionecrosis-in-patients-with-brain-metastases-undergoing-stereotactic-radiotherapy
#31
JOURNAL ARTICLE
Bedriye Doğan, Harun Demir, Naciye Işık, Gun Gunalp, Hediye Pınar Günbey, Gökhan Yaprak
OBJECTIVE: To investigate the incidence, timing and the factors predictors radionecrosis (RN) development in brain metastases (BMs) undergoing stereotactic radiotherapy (SRT). METHODS: The study evaluated 245 BMs who exclusively received SRT between 2010 and 2020. RN was detected pathologically or radiologically. RESULTS: The median of follow-up was 22.6 months. RN was detected in 18.4% of the metastatic lesions, and 3.3% symptomatic, 15...
February 29, 2024: British Journal of Radiology
https://read.qxmd.com/read/38424164/ranolazine-a-potential-anti-metastatic-drug-targeting-voltage-gated-sodium-channels
#32
REVIEW
Mustafa B A Djamgoz
BACKGROUND: Multi-faceted evidence from a range of cancers suggests strongly that de novo expression of voltage-gated sodium channels (VGSCs) plays a significant role in driving cancer cell invasiveness. Under hypoxic conditions, common to growing tumours, VGSCs develop a persistent current (INaP ) which can be blocked selectively by ranolazine. METHODS: Several different carcinomas were examined. We used data from a range of experimental approaches relating to cellular invasiveness and metastasis...
February 29, 2024: British Journal of Cancer
https://read.qxmd.com/read/38412597/abducens-nerve-palsy-due-to-clivus-metastasis-in-a-patient-with-breast-carcinoma-a-rare-case
#33
Jude Selvakumar Nilojan, Sittampalam Rajendra, Gayathri Naganathan
INTRODUCTION: Breast cancer, comprising 25 % of all diagnosed cancers, predominantly affects women globally. While bone metastasis is common, occurrences at the clivus or skull base are rarely documented. Treatment varies from surgery in early stages to a multifaceted approach for advanced cases, incorporating chemotherapy, radiotherapy, and surgery based on staging and histology. CLINICAL PRESENTATION: A 40-year-old female presented with a rapidly enlarging lump in her left breast and diplopia on right gaze...
February 25, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38411882/plasma-thbs1-as-a-predictive-biomarker-for-poor-prognosis-and-brain-metastasis-in-patients-with-her2-enriched-breast-cancer
#34
JOURNAL ARTICLE
Yang Li, Jun Qin, Guiming Chen, Weidong Wu, Xing Sun
BACKGROUND: Thrombospondin-1 (THBS1) is a secretory adhesive glycoprotein involved in the progression of multiple malignancies, including breast cancer. However, the clinical significance and prognostic role of plasma THBS1 in breast cancer have yet to be clarified. METHODS: Plasma THBS1 levels in 627 breast cancer patients were analyzed by enzyme-linked immunosorbent assay. Bone marrow blood was drawn from the anterior/posterior superior iliac spine to detect the presence of disseminated tumor cells (DTCs)...
February 27, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38410761/standard-of-care-treatment-for-her2-metastatic-breast-cancer-and-emerging-therapeutic-options
#35
REVIEW
Sarah K Premji, Ciara C O'Sullivan
Prior to the advent of the HER2-targeted monoclonal antibody trastuzumab, HER2+ breast cancer (BC) was considered an aggressive disease with a poor prognosis. Over the past 25 years, innovations in molecular biology, pathology, and early therapeutics have transformed the treatment landscape. With the advent of multiple HER2-directed therapies, there have been immense improvements in oncological outcomes in both adjuvant and metastatic settings. Currently, 8 HER2-targeted therapies are approved by the Food and Drug Administration (FDA) for the treatment of early-stage and/or advanced/metastatic disease...
2024: Breast Cancer: Basic and Clinical Research
https://read.qxmd.com/read/38405839/repurposing-mebendazole-against-triple-negative-breast-cancer-leptomeningeal-disease
#36
Adrian Rodrigues, Sophia B Chernikova, Yuelong Wang, Thy T H Trinh, David E Solow-Cordero, Ludmila Alexandrova, Kerriann M Casey, Elizabeth Alli, Abhishek Aggarwal, Tyler Quill, Ashley Koegel, Brian J Feldman, James M Ford, Melanie Hayden-Gephart
Purpose Triple-negative breast cancer (TNBC) is an aggressive subtype that often metastasizes to the brain. Leptomeningeal disease (LMD), a devastating brain metastasis common in TNBC, has limited treatment options. We sought to test whether the common anti-helminthic drug mebendazole (MBZ) may be effective against murine TNBC LMD. Methods A small-molecule screen involving TNBC cell lines identified benzimidazoles as potential therapeutic agents for further study. In vitro migration assays were used to evaluate cell migration capacity and the effect of MBZ...
February 5, 2024: Research Square
https://read.qxmd.com/read/38390439/cerebral-venous-sinus-thrombosis-in-a-patient-treated-with-ribociclib-for-metastatic-breast-cancer-case-reports-and-literature-review
#37
Baha Sharaf, Zeina Othman, Hala Abu Faris, Malak Al-Bitar, Qasem Al-Zoubi, Dima Abu Laban, Hala Abu-Jaish, Hikmat Abdel-Razeq
Breast cancer is the most diagnosed cancer among women worldwide. Cyclin dependent kinase 4/6 inhibitors (ribociclib, palbociclib, and abemaciclib) modulate endocrine resistance and are widely used treatment for patients with advanced-stage hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Reports of both venous and arterial thromboembolic events, as a complication of cyclin dependent kinase 4/6 inhibitors, are increasingly recognized, but none involved cerebral venous sinus...
2024: SAGE Open Medical Case Reports
https://read.qxmd.com/read/38389643/therapeutic-effects-of-cdk4-6-inhibitors-in-gastric-and-colonic-metastases-from-breast-cancer-a-case-report
#38
Akinori Sasaki, Shuko Masuda, Tsubasa Yoshioka, Akira Saito, Yasuaki Motomura
Breast cancer often metastasizes to the lungs, bones, liver, and brain; however, gastric and colonic metastases from breast cancer are rare. Nevertheless, here, we present the case of a 50-year-old woman diagnosed with recurrent breast cancer, exhibiting gastric and colonic metastases that were detected when she experienced intermittent abdominal pain. The differentiation between primary gastric cancer and metastasis from breast cancer was made through immunohistochemical staining. The patient underwent treatment with palbociclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, and anastrozole, with no significant adverse effects...
January 2024: Curēus
https://read.qxmd.com/read/38388667/estimating-the-risk-of-brain-metastasis-for-patients-newly-diagnosed-with-cancer
#39
JOURNAL ARTICLE
Joseph A Miccio, Zizhong Tian, Sean S Mahase, Christine Lin, Serah Choi, Brad E Zacharia, Jason P Sheehan, Paul D Brown, Daniel M Trifiletti, Joshua D Palmer, Ming Wang, Nicholas G Zaorsky
BACKGROUND: Brain metastases (BM) affect clinical management and prognosis but limited resources exist to estimate BM risk in newly diagnosed cancer patients. Additionally, guidelines for brain MRI screening are limited. We aimed to develop and validate models to predict risk of BM at diagnosis for the most common cancer types that spread to the brain. METHODS: Breast cancer, melanoma, kidney cancer, colorectal cancer (CRC), small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) data were extracted from the National Cancer Database to evaluate for the variables associated with the presence of BM at diagnosis...
February 22, 2024: Commun Med (Lond)
https://read.qxmd.com/read/38388422/synchronous-double-primary-small-cell-lung-cancer-and-invasive-ductal-breast-carcinoma-a-case-report
#40
JOURNAL ARTICLE
Junqing Gan, Meiyue Liu, Fei Liu, Junxiu Wen, Wenjuan Fu, Jinghao Jia
BACKGROUND: Although lung and breast cancers are common malignancies, the occurrence of primary synchronous neoplasms involving these organs has been rarely reported in literature. CASE PRESENTATION: A 75-year-old female patient presented at a local hospital with a ten-day history of dizziness and slurred speech. A CT contrast-enhanced scan revealed a 4.2 cm mass in the lower lobe of the right lung and a 3.8 cm space-occupying lesion in the right breast...
February 22, 2024: BMC Pulmonary Medicine
keyword
keyword
14442
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.